Anaplastic Astrocytoma Drug Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027

The global anaplastic astrocytoma drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Anaplastic astrocytoma is a rare type of brain tumor that starts from brain cells called astrocytes. Astrocytes are a type of glial cell. Additionally, it is both a type of astrocytoma and high-grade glioma. The major factor driving the growth of the market is the increasing prevalence of anaplastic astrocytoma across the globe.

According to the National Organization for Rare Diseases, astrocytomas are the most common primary brain tumors. It affects males more often than females and is estimated to affect 5-8 people per 100,000 in the general population. Additionally, anaplastic astrocytomas are more common in adults than children and usually develop between 30 and 50 years of age in adults. Furthermore, anaplastic astrocytomas usually develop between 5 and 9 years of age in children and account for approximately 10% of childhood central nervous stem tumors. Moreover, approximately 80% of astrocytomas in children are low grade. Hence, the increasing prevalence of anaplastic astrocytoma is driving the demand for anaplastic astrocytoma drugs for treatment which in turn is driving the growth of the market.

To Request a Sample of our Report on Anaplastic Astrocytoma Drug Market: https://www.omrglobal.com/request-sample/anaplastic-astrocytoma-drug-market

Some major players in the market include Amgen Inc, Astellas Pharma Inc., and Bayer AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2021, Adastra Pharmaceuticals, Inc. announced the completion of the Phase 1b clinical trial conducted by the NCI with its lead clinical candidate zotiraciclib (ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor. The trial was aimed to investigate the safety and efficacy of ZTR in combination with temozolomide (TMZ) in patients with recurrent high-grade gliomas.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Amgen Inc, Astellas Pharma Inc., and Bayer AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Anaplastic Astrocytoma Drug Market is Available @ https://www.omrglobal.com/industry-reports/anaplastic-astrocytoma-drug-market

Global Anaplastic Astrocytoma Drug Market Report by Segment

By Type

• A-10

• AS-21

• AdRTSIL-12

• ADU-623

• Others

By Application

• Hospital

• Clinic

• Others

Global Anaplastic Astrocytoma Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.